Mobile App for Cancer
(ROSA App Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new mobile app, the Mobile Symptom Monitoring and Alert App, designed to help manage symptoms for people receiving chemotherapy. The app uses real-time data from a Fitbit and patient-reported symptoms to suggest when to contact the care team. It aims to improve symptom management, quality of life, and communication with healthcare providers. Suitable candidates for this trial are those undergoing chemotherapy for any type of solid tumor cancer, have at least two cycles remaining, and use a compatible smartphone. Participants must complete daily symptom ratings and wear a Fitbit for 90 days. As an unphased trial, this study offers the opportunity to contribute to innovative research that could enhance cancer care for future patients.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on using a mobile app to monitor symptoms during chemotherapy, so you likely won't need to change your medication routine.
What prior data suggests that this mobile application is safe for patients receiving chemotherapy?
Research has shown that mobile apps for cancer patients are generally safe and easy to use. These apps assist patients in reporting symptoms and managing treatment more effectively. Studies have found that these apps can help patients adhere to their treatment plans.
One study found that daily symptom reporting through mobile apps provides an easy way for patients to share their feelings. This simplicity means patients can use these apps without added stress. The information collected helps healthcare teams better understand and address issues patients face during chemotherapy.
No direct evidence indicates unwanted side effects from using these cancer management apps. Instead, they offer a safe way to track symptoms and improve communication with healthcare providers. This suggests that using a mobile app for symptom monitoring is a safe choice for patients undergoing chemotherapy.12345Why are researchers excited about this trial?
The Mobile Symptom Monitoring and Alert App is unique because it leverages digital technology to track symptoms and vital signs in real-time, offering a more personalized approach to cancer care. Unlike traditional methods that rely on periodic doctor visits or patient self-reporting, this app allows for continuous monitoring via a smartphone, increasing the accuracy and timeliness of symptom management. Additionally, the integration with a Fitbit device provides comprehensive data on physical activity, heart rate, and other vital metrics, which can help in better understanding and addressing chemotherapy-related side effects. Researchers are excited about this approach because it has the potential to enhance patient engagement and outcomes by providing immediate feedback and alerts, leading to more proactive and precise interventions.
What evidence suggests that this mobile app is effective for cancer patients?
Research shows that mobile apps can help cancer patients manage their symptoms effectively. In this trial, participants will use the Mobile Symptom Monitoring and Alert App to track their symptoms daily for 90 days. Studies have found that such apps assist patients in tracking their symptoms and help them stick to their treatment plans. For example, one study discovered that using a mobile app to track symptoms during chemotherapy was both practical and helpful, making it easier for patients to report symptoms and communicate with their care teams. Another study highlighted that apps like the ChemoPro Application effectively improve symptom monitoring. These findings suggest that using a mobile app during chemotherapy can enhance symptom management and improve the overall quality of life for patients.13678
Who Is on the Research Team?
Carissa A Low
Principal Investigator
University of Pittsburgh
Are You a Good Fit for This Trial?
This trial is for cancer patients undergoing chemotherapy who are willing to use a mobile app and wear a Fitbit tracker daily for 90 days. They must be able to complete questionnaires and provide feedback on the app's usefulness.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants complete demographic and quality-of-life questionnaires, install the ROSA app, and are oriented to the study procedures.
Treatment
Participants use the ROSA app for daily symptom ratings and wear a Fitbit for continuous monitoring.
Follow-up
Participants complete end-of-study questionnaires and interviews, and the ROSA app is removed from their devices.
What Are the Treatments Tested in This Trial?
Interventions
- Mobile Symptom Monitoring and Alert App
Trial Overview
The study tests if a mobile app that monitors symptoms in real-time and suggests when to contact healthcare providers can help manage side effects, improve life quality, and patient engagement during chemotherapy.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will rate symptoms daily for 90 days using PRO-CATCAE questions to assess 8 common chemotherapy-related symptoms. Participants will wear a Fitbit (Inspire 3 or similar) for the duration of the study and install the Fitbit app on their smartphone. The Fitbit is a wristwatch-sized waterproof device that assesses heart and breathing rates, physical activity, and sleep, skin temperature, and oxygen levels and wirelessly transmits data to the server.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pittsburgh
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Citations
Mobile apps for cancer patients: Identifying positive ...
Evidence is available on Mobile apps for cancer management being used to successfully promote behavioral changes in the areas of treatment adherence.
Mobile applications for early breast cancer chemotherapy ...
Conclusions. Mobile applications are feasible and have ability to improve symptom monitoring during cancer treatment. However, more research is needed to ...
Mobile app activity engagement by cancer patients and ...
Mobile phone applications (“apps”) are potentially an effective, low-burden method to collect patient-reported outcomes outside the clinical ...
4.
aacrjournals.org
aacrjournals.org/cancerres/article/84/9_Supplement/PO5-13-01/744732/Abstract-PO5-13-01-An-App-Based-Approach-toAn App-Based Approach to Monitor Chemotherapy Symptoms
Our results suggest symptom monitoring using a dedicated mobile app is both acceptable and feasible for both patients and clinical personnel.
Effectiveness of a mobile application for tracking symptoms ...
This study confirms the effectiveness of a mobile application, such as the ChemoPro Application, in supporting symptom monitoring and promoting ...
Patient-facing cancer mobile apps that enable ...
This review identifies patient-facing cancer apps which can record patient reported outcomes, and explores their purpose, functionality, quality, and ability ...
Smartphone-Based Passive Sensing in Monitoring Patients ...
SBPS was used as a monitoring tool, with passively sensed data being correlated with adverse events, symptom burden, cancer-related fatigue, decision conflict, ...
Patients' daily reporting of symptoms via mobile application ...
The m-app contains modules on patients' demographic and cancer data, a symptom module (Figure 1A) with relevant tasks and useful tips according to the severity ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.